Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation regimen cuts treatment time for early glottic cancer

NCT ID NCT07197060

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a shorter, higher-dose radiation schedule (3.5 Gy per fraction for 17 sessions) for people with early-stage glottic cancer (T1-T2N0M0). The goal is to see if this approach controls the tumor as well as standard longer radiation, while being more convenient. About 70 adults who have not had prior larynx surgery or radiation will participate. The main outcome measured is local tumor control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with histologically confirmed squamous cell carcinoma of the glottisStage T1-T2N0M0 (AJCC 8th edition)based on clinical exam and imaging

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Histologically confirmed squamous cell carcinoma of the glottis * Stage T1-T2N0M0 (AJCC 8th edition) * (based on clinical exam and imaging) * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * No prior radiotherapy or surgery to the larynx (except biopsy) * Adequate organ function and a life expectancy of at least 6 months * Ability to comply with follow-up schedule and complete voice assessments * Signed informed consent Exclusion Criteria: * • Prior head and neck irradiation * Nodal involvement or distant metastasis * Poor vocal cord mobility or subglottic extension * Severe comorbidities or life expectancy \< 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early glottic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glottis carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early glottic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.